Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic‐induced dyskinesias
- 1 November 1994
- Vol. 18 (3) , 178-189
- https://doi.org/10.1002/syn.890180303
Abstract
Chronic neuroleptic treatment in rat produces vacuous chewing movements (VCMs), analogous to TD in humans. We hypothesized that these hyperkinetic movements were due to alterations in striatonigral and striatopallidal GABAergic spiny II neurons. Rats were treated for 36 weeks with haloperidol decanoate and withdrawn for 28 weeks. Striatonigral and striatopallidal neurons were assessed using in situ hybridization histochemistry for mRNA levels of D1 and D2 dopamine receptors, preproenkephalin (ENK), prodynorphin (DYN), protachykinin (substance P), and glutamate decarboxylase (GAD67) in the dorsolateral and ventromedial striatum as well as the nucleus accumbens. Rats that did not develop VCMs (- VCM) had increased D2 receptor and DYN mRNA, and reduced substance P mRNA in the dorsolateral striatum. Rats with persistent VCMs (+VCM,) had increased D2 receptor, ENK, and DYN mRNA in both striatal regions, and increased ENK and DYN mRNA in the nucleus accumbens, compared with controls. Relative to -VCM rats, however, +VCM rats only had increased ENK mRNA in the nucleus accumbens. Considering the overall pattern of mRNA changes, the data suggest that alterations in both the D1-mediated striatonigral and the D2-mediated striatopallidal pathways play a role in the expression of the VCM syndrome. To the extent that gene expression parallels changes in neuronal activity, this implies that the VCM syndrome is associated with increased activity in both pathways. © 1994 Wiley-Liss, Inc 1 This article is a US Government work and as such, is in the public domain in the United States of America.Keywords
This publication has 75 references indexed in Scilit:
- Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: Implications for the pathogenesis of neuroleptic-induced movement disordersExperimental Neurology, 1992
- Regulation of striatonigral prodynorphin peptides by dopaminergic agentsBrain Research, 1990
- Lack of effect of chronic dopamine receptor blockade on D2 dopamine receptor mRNA levelNeuroscience Letters, 1990
- Increases in rat striatal preproenkephalin mRNA levels following chronic treatment with the depot neuroleptic, haloperidol decanoateLife Sciences, 1990
- Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificityPsychopharmacology, 1989
- Alterations in cerebral glutamic acid decarboxylase and3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapineJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1987
- Induction of oral dyskinesias in naive rats by D1 stimulationLife Sciences, 1983
- Regulation of methionine-enkephalin precursor messenger RNA in rat striatum by haloperidol and lithiumBiochemical and Biophysical Research Communications, 1983
- Oral dyskinesia in rats following brain lesions and neuroleptic drug administrationPsychopharmacology, 1982
- Chronic treatment with haloperidol accelerates the biosynthesis of enkephalins in rat striatumBrain Research, 1979